Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up to $23.34

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares gapped up before the market opened on Thursday . The stock had previously closed at $23.34, but opened at $24.36. Dianthus Therapeutics shares last traded at $23.94, with a volume of 9,679 shares.

Analyst Ratings Changes

DNTH has been the topic of several recent research reports. Jefferies Financial Group boosted their price target on Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. Stifel Nicolaus initiated coverage on Dianthus Therapeutics in a research report on Thursday, February 15th. They issued a “buy” rating and a $44.00 price target on the stock. Finally, Wedbush boosted their price target on Dianthus Therapeutics from $24.00 to $33.00 and gave the company an “outperform” rating in a research report on Friday, March 22nd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $37.00.

Dianthus Therapeutics Stock Performance

The company has a 50-day simple moving average of $25.82 and a 200-day simple moving average of $17.11.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.40. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.73 million. Sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -1.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors have recently modified their holdings of DNTH. Tower Research Capital LLC TRC purchased a new stake in Dianthus Therapeutics in the 4th quarter valued at approximately $25,000. Citigroup Inc. purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter worth $53,000. Dimensional Fund Advisors LP purchased a new position in shares of Dianthus Therapeutics during the 4th quarter worth $153,000. Northern Trust Corp purchased a new position in shares of Dianthus Therapeutics during the 4th quarter worth $159,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth $303,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.